Class I evidence that in patients with AChRAb+ myasthenia gravis, the addition of amifampridine to pyridostigmine was not superior to treatment with pyridostigmine alone and was associated with a higher incidence of adverse events.

This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.